Literature DB >> 22183177

Successful double bypass in a patient with severe hemophilia A: a case report.

Giovanni Barillari1, Samantha Pasca, Filippo Erice, Ugolino Livi.   

Abstract

Life expectancy in the hemophilia people is similar to the non-haemophilics and age-related cardiovascular disorders to become more prevalent, but cardiac surgery is considered a very high risk for these patients. In this article we report the successful cardiac double bypass internal mammary artery--coronary artery in a patient with severe hemophilia A. (FVIII<1%; missense mutation: exon 16, c.5508 G>A (domain A3), p.Trp1817Stop). Continuous infusion of rFVIII B-domain deleted was used to control haemostasis during surgery and in post-operative period. There was no bleeding complications and the patient did not need to receive transfusion of red blood cells or platelets.

Entities:  

Mesh:

Year:  2012        PMID: 22183177     DOI: 10.1007/s11239-011-0664-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  9 in total

1.  Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.

Authors:  S C Gouw; J G Van Der Bom; H M Van Den Berg; R A Zewald; J K Ploos Van Amstel; E P Mauser-Bunschoten
Journal:  Haemophilia       Date:  2010-11-11       Impact factor: 4.287

2.  Cardiac surgery in a patient with haemophilia A.

Authors:  A Eren; R Friedl; A Hannekum; H Gulbins
Journal:  Thorac Cardiovasc Surg       Date:  2006-04       Impact factor: 1.827

3.  Cardiac surgery in patients with haemophilia.

Authors:  M Tang; P Wierup; K Terp; J Ingerslev; B Sørensen
Journal:  Haemophilia       Date:  2009-01       Impact factor: 4.287

4.  Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.

Authors:  N Stieltjes; C Altisent; G Auerswald; C Négrier; P Pouzol; J Reynaud; V Roussel-Robert; G F Savidge; A Villar; S Schulman
Journal:  Haemophilia       Date:  2004-09       Impact factor: 4.287

5.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 6.  Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

Authors:  A Sharathkumar; D Lillicrap; V S Blanchette; M Kern; J Leggo; A M Stain; L Brooker; M D Carcao
Journal:  J Thromb Haemost       Date:  2003-06       Impact factor: 5.824

7.  Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.

Authors:  A-M Hvas; H T Sørensen; L Norengaard; K Christiansen; J Ingerslev; B Sørensen
Journal:  J Thromb Haemost       Date:  2007-09-06       Impact factor: 5.824

8.  Coronary artery bypass surgery, angioplasty and long term anti-platelet treatment in a type B hemophilia patient.

Authors:  Antonio Eduardo Pesaro; Marcus Vinicius Gaz; Ralf Karbstein; Marco Perin; Carlos Vicente Serrano; Elbio Damico
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

9.  Transient acquired hemophilia associated with Mycoplasma pneumoniae pneumonia.

Authors:  Min Sun Kim; Paul E Kilgore; Ju Sung Kang; Sun Young Kim; Dae Yeol Lee; Jung Soo Kim; Pyoung Han Hwang
Journal:  J Korean Med Sci       Date:  2008-02       Impact factor: 2.153

  9 in total
  2 in total

1.  Free musculocutaneous flap transfer for refractory chronic empyema with chest wall sinus in a 43-year-old male with hemophilia A.

Authors:  Xiaowen He; Zhongliang He; Lifeng Shen; Guoxing Chen; Xueming He
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 2.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.